Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Business objectives have changed
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A retrospective study to evaluate healthcare cost and resource utilization for patients with metastatic renal cell carcinoma who have been treated with IV or oral agents
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients treated with IV agents | Metastatic renal cell carcinoma patients treated with IV agents |
| |
| Patients treated with oral agents | Metastatic renal cell carcinoma patients treated with oral agents |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Non-Interventional | Other | Other |
|
| Measure | Description | Time Frame |
|---|---|---|
| Distribution of Healthcare costs for patients treated with oral drugs used in the first-line treatment of Metastatic renal cell carcinoma (mRCC) | All-cause healthcare costs will be calculated in the first-line oral cohort as per-patient-per-month (PPPM) costs. | Up to 63 months |
| Composite of Resource Utilization for patients treated with oral drugs used in the first-line treatment of mRCC | Total numbers and rates of inpatient, outpatient, and emergency room visits per patient will be calculated. | Up to 63 months |
| Distribution of Healthcare costs for patients treated with IV drugs used in the first-line treatment of mRCC | All-cause healthcare costs will be calculated in the first-line IV cohort as per-patient-per-month (PPPM) costs. | Up to 63 months |
| Composite of Resource Utilization for patients treated with IV drugs used in the first-line treatment of mRCC | Total numbers and rates of inpatient, outpatient, and emergency room visits per patient will be calculated. | Up to 63 months |
| Measure | Description | Time Frame |
|---|---|---|
| Medication Possession Ratio (MPR) for patients treated with oral drugs used in the first-line treatment of mRCC | MPR will be calculated for each index drug as the ratio of the sum of the total number of days' supply to the total number of days in the follow-up period. | Up to 63 months |
| Medication Possession Ratio (MPR) for patients treated with IV drugs used in the first-line treatment of mRCC |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Metastatic RCC patients in the US identified from administrative claim databases
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bristol-Myers Squibb | Bristol-Myers Squibb | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Bristol-Myers Squibb | Princeton | New Jersey | 08540 | United States |
Not provided
| ID | Term |
|---|---|
| D002292 | Carcinoma, Renal Cell |
| ID | Term |
|---|---|
| D000230 | Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
Not provided
Not provided
Not provided
MPR will be calculated for each index drug as the ratio of the sum of the total number of days' supply to the total number of days in the follow-up period. |
| Up to 63 months |
| D009369 | Neoplasms |
| D007680 | Kidney Neoplasms |
| D014571 | Urologic Neoplasms |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052801 | Male Urogenital Diseases |